Literature DB >> 28565788

Immunosuppressive agents are associated with peptic ulcer bleeding.

Minoru Tomizawa1, Fuminobu Shinozaki2, Rumiko Hasegawa3, Yoshinori Shirai3, Yasufumi Motoyoshi4, Takao Sugiyama5, Shigenori Yamamoto6, Naoki Ishige7.   

Abstract

Peptic ulcer bleeding can be fatal. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and immunosuppressive agents are administered for long-term usage. The present study assessed the association between peptic ulcer bleeding and administration of NSAIDs, corticosteroids and immunosuppressive agents. Furthermore, the efficacy of lowering the risk of peptic ulcer bleeding with proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) was evaluated. Medical records were retrospectively analyzed for patients subjected to an upper gastrointestinal (GI) endoscopy performed at the National Hospital Organization Shimoshizu Hospital (Yotsukaido, Japan) from October 2014 to September 2015. During this period, a total of 1,023 patients underwent an upper GI endoscopy. A total of 1,023 patients, including 431 males (age, 68.1±12.9 years) and 592 females (age, 66.4±12.3 years), who had been administered NSAIDs, corticosteroids, immunosuppressive agents, PPIs and H2RAs, were respectively enrolled. Endoscopic findings of the patients were reviewed and their data were statistically analyzed. Logistic regression analysis was used to determine the odds ratio of peptic ulcer bleeding for each medication; immunosuppressive agents had an odds ratio of 5.83, which was larger than that for NSAIDs (4.77). The Wald test was applied to confirm the correlation between immunosuppressive agents and peptic ulcer bleeding. Furthermore, χ2 tests were applied to the correlation between peptic ulcer bleeding and administration of PPIs or H2RAs. Immunosuppressive agents had the largest χ2, and the P-value was 0.03. Administration of PPIs was significantly correlated with non-peptic ulcer bleeding (P=0.02); furthermore, a tendency toward non-peptic ulcer bleeding with administration of H2RA was indicated, but it was not statistically significant (P=0.12). In conclusion, immunosuppressive agents were correlated with peptic ulcer bleeding and PPIs were effective at lowering the risk of peptic ulcer bleeding.

Entities:  

Keywords:  Wald test; corticosteroids; histamine type 2 receptor antagonists; immunosuppressive agents; logistic regression analysis; nonsteroidal anti-inflammatory drugs; proton pump inhibitor

Year:  2017        PMID: 28565788      PMCID: PMC5443275          DOI: 10.3892/etm.2017.4214

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  36 in total

1.  Catastrophic gastrointestinal complication of systemic immunosuppression.

Authors:  Lyn Alexandra Smith; Mitali Gangopadhyay; Daniel R Gaya
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

2.  Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.

Authors:  Soo-Kyung Cho; Yoon-Kyoung Sung; Chan-Bum Choi; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

3.  Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort.

Authors:  Helga Radner; Kazuki Yoshida; Maria Dahl Mjaavatten; Daniel Aletaha; Michelle Frits; Bing Lu; Christine Iannaccone; Nancy Shadick; Michael Weinblatt; Ihsane Hmamouchi; M Dougados; Josef S Smolen; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2015-06-19       Impact factor: 5.532

4.  Persistent duodenal ulcers bleeding in postkidney transplant patient treated by infliximab.

Authors:  Piyapan Prueksapanich; Rapat Pittayanon; Yingyos Avihingsanon; Rungsun Rerknimitr
Journal:  BMJ Case Rep       Date:  2013-04-23

Review 5.  Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis.

Authors:  Waleed Alhazzani; Farhan Alenezi; Roman Z Jaeschke; Paul Moayyedi; Deborah J Cook
Journal:  Crit Care Med       Date:  2013-03       Impact factor: 7.598

6.  PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis.

Authors:  Chen Mo; Gang Sun; Yan-Zhi Wang; Ming-Liang Lu; Yun-Sheng Yang
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

7.  Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review.

Authors:  Sooyoung Shin
Journal:  Ther Clin Risk Manag       Date:  2015-05-24       Impact factor: 2.423

8.  Body mass index and participation in organized mammographic screening: a prospective cohort study.

Authors:  Sophie Sell Hellmann; Sisse Helle Njor; Elsebeth Lynge; My von Euler-Chelpin; Anja Olsen; Anne Tjønneland; Ilse Vejborg; Zorana Jovanovic Andersen
Journal:  BMC Cancer       Date:  2015-04-17       Impact factor: 4.430

Review 9.  Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis.

Authors:  Yoshiya Tanaka; Shintaro Hirata
Journal:  Drugs       Date:  2014-12       Impact factor: 9.546

Review 10.  The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.

Authors:  Anne Tuskey; David Peura
Journal:  Arthritis Res Ther       Date:  2013-07-24       Impact factor: 5.156

View more
  2 in total

1.  Risk Factors for Recurrence of Peptic Ulcer Disease: A Retrospective Study in Tertiary Care Referral Center.

Authors:  Yaser M Alsinnari; Mohammed S Alqarni; Meshari Attar; Ziad M Bukhari; Mohammed Almutairi; Faisal M Baabbad; Mohammed Hasosah
Journal:  Cureus       Date:  2022-02-07

2.  Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge.

Authors:  Verónica Gamelas; Vera Salvado; Luís Dias
Journal:  GE Port J Gastroenterol       Date:  2018-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.